Natixis Acadia Pharmaceuticals Inc Transaction History

Natixis

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 24, 2023	BUY	$14.2 - $18.63 $14 - $18	1 New	1 $0
Q1 2022 May 13, 2022	SELL	$20.94 - $27.5 $12.1 Million - $15.9 Million	-579,961 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $6.87 Million - $11.1 Million	409,300 Added 239.83%	579,961 $13.5 Million
Q3 2021 Nov 12, 2021	BUY	$15.78 - $24.77 $2.51 Million - $3.94 Million	158,896 Added 1350.58%	170,661 $2.84 Million
Q2 2021 Aug 13, 2021	BUY	$19.4 - $27.42 $228,240 - $322,596	11,765 New	11,765 $287,000
Q1 2021 May 14, 2021	SELL	$25.02 - $54.99 $4.26 Million - $9.36 Million	-170,240 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$41.04 - $56.79 $6.99 Million - $9.67 Million	170,240 New	170,240 $9.1 Million
Q3 2018 Nov 14, 2018	SELL	$13.03 - $21.81 $294,021 - $492,142	-22,565 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$15.07 - $22.34 $340,054 - $504,102	22,565 New	22,565 $345,000
Q1 2018 May 15, 2018	SELL	$22.47 - $32.33 $280,627 - $403,769	-12,489 Closed	0 $0
Q4 2017 Feb 14, 2018	SELL	$26.84 - $39.14 $566,672 - $826,362	-21,113 Reduced 62.83%	12,489 $376,000
Q3 2017 Nov 14, 2017	BUY	$29.49 - $38.37 $990,922 - $1.29 Million	33,602	33,602 $1.27 Million

280

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.65B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.